Concepedia

Sheryl Treichel

ST

Statistics

Publications

11

Citations

740

H-Index

10

Active since

2009

Affiliations

Amgen (United States)(Current)

University Hospital of Zurich

Russian Cancer Research Center NN Blokhin

University of Utah

University of Louisville

Sheryl Treichel is an author at Amgen (United States) specializing in oncology, medicine, and radiation oncology.

Top concepts

Publications per year

2009–2022

11

Publications

11

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma

Jason Chesney, Antoni Ribas, Georgina V. Long et al. · Journal of Clinical Oncology · 2022 · 241 citations · Full text

Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial

Reinhard Dummer, David Gyorki, John Hyngstrom et al. · Nature Medicine · 2021 · 141 citations

, , +6

Investigation of quality of life and family burden issues during insulin pump therapy in children with Type 1 diabetes mellitus—a large‐scale multicentre pilot study<sup>1</sup>

Esther Müller–Godeffroy, Sheryl Treichel, Verena M. Wagner · Diabetic Medicine · 2009 · 131 citations

1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL)

A. Ribas, Jason Chesney, Georgina V. Long et al. · Annals of Oncology · 2021 · 56 citations

, , +9

Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL).

Robert Hans Ingemar Andtbacka, Reinhard Dummer, David Gyorki et al. · Journal of Clinical Oncology · 2018 · 41 citations

, , +17

1–5 of 11